Entity

Time filter

Source Type

Comodoro Rivadavia, Argentina

Bertini K.,Htal. Militar Central | Drnovsek M.L.,Htal. Ramos Mejia | Echin M.,Htal. Rivadavia | Ercolano M.,Htal. Ramos Mejia | And 2 more authors.
Revista Argentina de Endocrinologia y Metabolismo | Year: 2013

Osteoimmunology is a research field that deals with the study of the interaction between the immune system and bone tissue. Enough evidence demonstrates that they share regulatory mechanisms. This interaction occurs through direct contact between the cells of both systems and by the action of immune regulatory mediators, cytokines and growth factors. The aim of this review is to provide an overview of the interaction between bone and immune cells and the role they play in the mutual development and function. A greater knowledge of the interaction of these two systems will allow a better understanding of the role of immunology in the pathogenesis of bone mass loss. Copyright ® 2013 por la Sociedad Argentina de Endocrinología y Metabolismo. Source


Bertini K.,Htal. Militar Central | Drnovsek M.,Htal. Ramos Mejia | Echin M.,Htal. Rivadavia | Ercolano M.,Htal. Ramos Mejia | And 2 more authors.
Revista Argentina de Endocrinologia y Metabolismo | Year: 2014

The objective of this communication is to review the immune mechanisms involved in the pathogenesis of bone damage in some autoimmune diseases. As they are numerous (autoimmune polyendocrinopathy , celiac disease, Crohn's disease, ulcerative colitis, HIV, rheumatic diseases, bronchial asthma, pernicious anemia, periodontitis, etc.), we selected only four: Rheumatoid Arthritis, because of its typical bone lesions; post-menopause, because the immune components are not so often described; HIV, because of the current longer survival time with higher possibilities of bone lesions, and Periodontitis, in order to have an overview of dental aspects of this pathology. In many cases, knowledge of these mechanisms has contributed to the development of specific drugs that have led to therapeutic success and an improved quality of life. Copyright ® 2014 por la Sociedad Argentina de Endocrinología y Metabolismo Source


Drnovsek M.,Htal. Ramos Mejia | Echin M.,Htal. Rivadavia | Ercolano M.,Htal. Ramos Mejia | Rubin Z.,Htal. de Clinicas
Revista Argentina de Endocrinologia y Metabolismo | Year: 2011

Osteoporosis and bone fractures are frequently overlooked complications of androgen deprivation therapy in men with non-metastatic prostate cancer. Several therapies commonly used in the treatment of prostate cancers, particularly in androgen deprivation therapy for prostate cancer, are associated with significant bone loss and with an increase in fracture risk. The use of bisphosphonates seems to attenuate bone loss, although the long-term impact remains unclear because of insufficient follow-up. Several agents, such as denosumab and toremifene, have shown to be promising in reducing fracture risk in these patients. Adjuvant endocrine therapy with androgen deprivation can be considered a risk factor for the development of osteopenia, osteoporosis, and bone fracture, which can be mitigated by appropriate bisphosphonate therapy. Clear identification of risk factors for osteoporosis in individual patients could help in decision-making about whether to initiate treatment with bisphosphonates in patients under androgen deprivation therapy. Patients need to be educated about this risk and other measures to avoid this complication, including lifestyle modifications that may benefit their general and bone health. Copyright © 2011 por la Sociedad Argentina de Endocrinología y Metabolismo. Source


Bertini K.,Htal. Militar Central | Drnovsek M.,Htal. Ramos Mejia | Echin M.,Htal. Rivadavia | Ercolano M.,Htal. Ramos Mejia | And 2 more authors.
Revista Argentina de Endocrinologia y Metabolismo | Year: 2014

As both the immune and hematopoietic cells originate in the bone marrow, it is not surprising that there should be an interaction between these two systems. While osteoblasts have the main capacity to influence differentiation and activation of osteoclasts, osteoblast-producing stromal cells, non-hematopoietic stromal cells, lymphocytes, interleukins and growth factors also affect bone cell function. Copyright © 2014 por la Sociedad Argentina de Endocrinologia y Metabolismo. Source

Discover hidden collaborations